Skip to main content
. 2020 Oct 19;2020(10):CD012859. doi: 10.1002/14651858.CD012859.pub2

CTRI/2015/03/005616.

Methods Randomized controlled trial
Participants Patients scheduled for elective intracranial surgery, ASA I and II, GCS 15
Interventions Ondansetron (4 mg) given at the time of dural closure or palonosetron (0.075 mg) given at the time of dural closure
Outcomes PONV, side effects
Notes Study status (recruiting), first posted (2015), missing information (age, anaesthesia regimen, intervention)